Nivalis Therapeutics,Inc. (NASDAQ:NVLS) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition
On May1, 2017, Nivalis Therapeutics,Inc. issued a press release
announcing its financial results for the quarterended March31,
2017.A copy of the press release is attached as Exhibit99.1 and
is incorporated herein by reference.
The information in this Current Report on Form8-K, including the
information incorporated by reference herein and Exhibit99.1
attached hereto, shall not be deemed to be filed for purposes of
Section18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Number and Description
|
99.1 |
Press Release, dated May1, 2017. |
2
About Nivalis Therapeutics, Inc. (NASDAQ:NVLS)
Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company’s S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company’s lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR. Nivalis Therapeutics, Inc. (NASDAQ:NVLS) Recent Trading Information
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) closed its last trading session down -0.01 at 2.25 with 226,078 shares trading hands.
